Sequencing-based studies have identified novel risk genes for rare, severe epilepsies and 14 revealed a role of rare deleterious variation in common epilepsies. To identify the shared and 15 distinct ultra-rare genetic risk factors for rare and common epilepsies, we performed a whole- 16 exome sequencing (WES) analysis of 9,170 epilepsy-affected individuals and 8,364 controls of 17 European ancestry. We focused on three phenotypic groups; the rare but severe developmental 18 and epileptic encephalopathies (DEE), and the commoner phenotypes of genetic generalized 19 epilepsy (GGE) and non-acquired focal epilepsy (NAFE). We observed that compared to controls, 20 individuals with any type of epilepsy carried an excess of ultra-rare, deleterious variants in 21 constrained genes and in genes previously associated with epilepsy, with the strongest 22 enrichment seen in DEE and the least in NAFE. Moreover, we found that inhibitory GABAA 23 receptor genes were enriched for missense variants across all three classes of epilepsy, while no 24 enrichment was seen in excitatory receptor genes. The larger gene groups for the GABAergic 25 pathway or cation channels also showed a significant mutational burden in DEE and GGE. 26 Although no single gene surpassed exome-wide significance among individuals with GGE or 27 NAFE, highly constrained genes and genes encoding ion channels were among the top 28 associations, including CACNA1G, EEF1A2, and GABRG2 for GGE and LGI1, TRIM3, and 29 GABRG2 for NAFE. Our study confirms a convergence in the genetics of common and rare 30 epilepsies associated with ultra-rare coding variation and highlights a ubiquitous role for 31 GABAergic inhibition in epilepsy etiology in the largest epilepsy WES study to date. 32 33 Epilepsy is a group of disorders characterized by repeated seizures due to excessive electrical 34 activity in the brain, one of the most common and burdensome neurological conditions worldwide 1; 35 2 . A core challenge for epilepsy genetics is identifying and disentangling the genetic architecture 36 and biological mechanisms underlying the variety of epilepsy types (e.g., focal vs. generalized) 37 and electroclinical syndromes. While the occurrence of epilepsy for many affected individuals 38 carries an underlying genetic component 3-5 , the highly heterogeneous nature of epileptic seizures, 39 epilepsy types, severity, and comorbidity makes it difficult to determine the specific genetic risks 40 for each patient. For individuals with common, complex types of epilepsy, where inheritance may 41 be due to strongly acting mutations, oligogenic or polygenic, the discovery of genetic risk factors 42 is particularly challenging. 43 Considerable progress in our understanding of the genetic risk factors for epilepsy has 44 been made in recent years thanks to the rapid growth and advancement in sequencing technology. 45 Dozens of epilepsy-causing genes have been identified in individuals diagnosed with severe 46 epilepsy syndromes 6-10 , known as the developmental and epileptic encephalopathies (DEE). DEE 47
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are rare in the population and typically begin early in life. Incidence of the entire group is not well 48 established, but a recent epidemiological study of severe epilepsies limited to onset under 18 49 months found an incidence of 1 in 2000 births 11 . The incidence of Dravet syndrome, one of the 50 important specific forms of DEE, has been shown in several studies as 1 in 22,000 10 . Individuals 51 with DEE usually have developmental impairment, ranging from profound to mild. With such 52 severity, sequencing-based studies continue to discover de novo pathogenic variants for DEE 53 and have implicated genes encoding neuronal ion channels and receptors and genes involved in 54 cellular signaling 6-10; 12 . The common subgroups of epilepsy, broadly comprising genetic 55 generalized epilepsy (GGE) and non-acquired focal epilepsy (NAFE), account for a major 56 proportion of all incident epilepsies 2; 13 and have been shown robust heritability in twin, family, and 57 genome-wide association studies (GWAS) 4; [14] [15] [16] . Disappointingly, only a limited number of genes 58 had been discovered to date for the common epilepsies, mostly from rare monogenic families with 59 focal epilepsies, and attempts to identify clear risk genes for GGE have been least successful 12; 60 17; 18 . In most cases, especially for non-familial onset, the specific pathogenic variants are not yet 61 known, and gene findings from small-scale studies have often not been reproducible [19] [20] [21] . 62 Current evidence of the genetic etiology of epilepsies has revealed both extensive 63 phenotypic and genetic heterogeneity. Many of the identified genes are associated with a 64 spectrum of mild to severe epilepsies, showing phenotypic pleiotropy or variable expressivity, and 65 most of the electroclinical syndromes have diverse genetic causes 10; 22 . Two recent studies using 66 whole-exome sequencing (WES) of hundreds of individuals with common familial epilepsies found 67 an enrichment in ultra-rare genetic variation in genes associated with rare epilepsy syndromes 17 68 and in missense variants in a group of genes encoding all GABAA receptors, the most important 69 neurotransmitter receptors for neuronal inhibition in the mammalian brain 18 . Given the complex 70 genetic architecture of the epilepsies, it is therefore critical to pinpoint the distinct and overlapping 71 genetic risk factors underlying different groups of epilepsy on a scale much larger than previous 72 sequencing studies and beyond familial cases. 73 Here, we evaluate a WES case-control study of epilepsy from the Epi25 collaborative- 74 an ongoing global effort that collected an unprecedented number of patient cohorts for primarily 75 the three major classes of non-lesional epilepsies: DEE, GGE, and NAFE 22 . We aimed to 76 characterize the genetic risk of ultra-rare coding variants across these common and rare epilepsy 77 subgroups by evaluating the burden at the individual gene level and in candidate gene sets to 78 understand the role of rare genetic variation in epilepsy and identify specific epilepsy risk genes. 79 the first ten principal components (PCs), and removed variants significantly associated with 155 capture labels (p-value < 0.05). We also excluded variants with a call rate < 0.98, case-control 156 call rate difference > 0.005, or Hardy-Weinberg Equilibrium (HWE) test p-value < 1×10 -6 based Gene-set burden analysis 193 To estimate the excess of rare, deleterious protein-coding variants in individuals with epilepsy, 194 we conducted burden tests across the entire exome, for biologically relevant gene sets and at the 195 individual gene level. We focused on two definitions of "ultra-rare" genetic variation (URV) for the 196 primary analyses-variants not seen in the DiscovEHR database and observed only once among 197 the combined case and control test cohort (allele count AC=1) or absent in DiscovEHR and 198 observed no more than three times in the test cohort (allele count AC≤3)-where the strongest 199 burden of deleterious pathogenic variants have been observed previously 17; 31 and in our study 200 compared to less stringent allele frequency thresholds (Figure S9 & S10) . We performed these 201 case-control comparisons separately for each of the three primary epilepsy disorders (DEE, GGE, 202 NAFE) and again for all epilepsy-affected individuals combined. 203 Gene-set burden tests were implemented using logistic regression to examine the 204 enrichment of URVs in individuals with epilepsy versus controls. We performed the test by 205 regressing case-control status on certain classes of URVs aggregated across a target gene set 206 in an individual, adjusting for sex, the top ten PCs, and exome-wide variant count. This analysis 207 tested the burden of URVs separately for five functional coding annotations: synonymous, benign 208 missense predicted by PolyPhen-2 and SIFT, damaging missense predicted by PolyPhen-2 and 209 SIFT, protein-truncating variants, and missense with MPC≥2 (Table S5) . To help determine 210 whether our burden model was well calibrated, we used synonymous substitutions as a negative 211 control, where significant burden effects would more likely indicate insufficient control of 212 population stratification or exome capture differences. The inclusion of overall variant count as a 213 covariate-which tracks with ancestry-made our test conservative but allows for better control 214 of residual population stratification not captured by PCs, and effectively reduces inflation of 215 signals in synonymous variants ( Figure S11 ). We collected and tested eleven different gene sets, 216 including constrained genes, brain-enriched genes, and genes reported to be associated with 217 epilepsy or epilepsy-related mechanisms 9; 17; 18; 32; 33 (Table S6) . Unlike the gene-based burden 218 tests, because most of the gene-set tests were not independent, we used a false discovery rate 219 (FDR) correction for multiple testing that accounted for the number of functional categories (5), 220 gene sets (11) and epilepsy phenotypes (4), totaling 220 tests, and defined a significant 221 enrichment at FDR < 0.05.
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Gene-based collapsing analysis 224 For gene-based tests, we restricted to deleterious URVs annotated as either PTV, 225 missense with MPC≥2, or in-frame insertion/deletion. For each gene, individuals who had at least 226 one copy of these deleterious variants were counted as a carrier, and we used a two-tailed 227 Fisher's Exact test (FET) to assess if the proportion of carriers among epilepsy subgroup cases 228 was significantly higher than controls. Instead of assuming a uniform distribution for p-values 229 under the null, we generated empirical p-values by permuting case-control labels 500 times, 230 ordering the FET p-values of all genes for each permutation, and taking the average across all 231 permutations to form a rank-ordered estimate of the expected p-value distribution. This was done 232 256 We performed WES on an initial dataset of over 30,000 epilepsy affected and control individuals. 257 After stringent quality control (QC), we identified a total of 9,170 individuals with epilepsy and 258 8,436 controls without reported neurological or neuropsychiatric-related conditions, all of whom 259 were unrelated individuals of European descent. Among the individuals with epilepsy, 1,021 were 260 diagnosed with DEE, 3,108 with GGE, 3,597 with NAFE, and 1,444 with other epilepsy syndromes 261 (lesional focal epilepsy, febrile seizures, and others). Cases and controls were carefully matched 262 on genetic ancestry to eliminate the possibility of false positive findings induced by population 263 stratification. Due to the lack of cosmopolitan controls from non-European populations, cases 264 identified from PCA with a non-European ancestry were removed. Furthermore, to ensure the 265 distribution of rare variants was balanced between cases and controls 37 , we removed a subset of 266 case and control-only cohorts (from Sweden, Finland, Cyprus, and Turkey) where the mean 267 synonymous singleton count that significantly deviated from the overall average being the 268 consequence of incomplete ancestry matching ( Figure S4 ). We called a total of 1,844,644 sites 269 in 18,509 genes in the final dataset, comprising 1,811,325 SNVs and 33,319 indels, 48.5% of 270 which were absent in the DiscovEHR database 30 . Among the non-DiscovEHR sites, 85% were 271 singletons (defined as only one instance of that variant), and 99% had a minor allele count (AC) 272 not more than three (equivalent to MAF ≤0.01%; Figure S8 ); the missense with MPC≥2 273 annotation accounted for 2.0% of the total missense variants (5.5% of the damaging and 1.0% of 274 the benign missense variants predicted by PolyPhen-2 and SIFT). In our primary burden analyses, 275 we focused on the "ultra-rare" non-DiscovEHR variants (URVs) that are unique to the 17,606 276 individuals under study and are seen either only once (AC=1) or no more than three times (AC≤3) 277 in our dataset. These URVs were shown to confer the largest risk of epilepsy compared to 278 singletons observed in DiscovEHR, doubletons, or beyond (Figure S9 & S10). As previously 279 described, epilepsy enrichment signals diminished with an increase in allele frequency 17 . 282 We first tested the burden of singleton URVs for each epilepsy subgroup, as well as for all 283 epilepsy-affected individuals combined, versus controls among gene sets collected based on 284 current understanding and hypothesis of epilepsy causation (Table S6) . To evaluate the burden 285 in constrained genes, we defined "loss-of-function (LoF) intolerant" genes with either a pLI score 29 286 > 0.9 (3,488 genes) or separately a pLI score > 0.995 (1,583 genes) and those as "missense-287 constrained" for genes with a missense Z-score > 3.09 (1,730 genes) 33 . We used a version of the 288 scores derived from the non-neuropsychiatric subset of the Exome Aggregation Consortium 289 (ExAC) samples. Because some of our control cohorts are also in ExAC (Table S2) , we restricted 290 our constrained gene burden tests to controls outside of the ExAC cohort (N=4,042). 291 We found that, consistent with a recent study that evaluated de novo burden in autism 38 , 292 burden signals of PTVs were mostly contained in genes with a pLI > 0.995 compared to pLI > 0.9 293 (Figure S12 & S13). Focusing on pLI > 0.995 in the all-epilepsy case-control analysis, both 294 protein-truncating and damaging missense (MPC 28 ≥2) URVs in LoF-intolerant genes showed a 295 mutational burden with an odds ratio of 1.3 (adjP = 1.6×10 -4 ) and 1.1 (adjP = 0.039), respectively. Figure 1 ). There was no evidence of excess burden in synonymous URVs, suggesting that 302 enrichment of deleterious pathogenic variants was unlikely to be the result of un-modeled 303 population stratification or technical artifact. Among in-silico missense predictors, MPC≥2 304 annotations consistently showed a higher burden than those predicted by PolyPhen-2 and SIFT. 305 The burden among missense-constrained genes exhibited a similar pattern, with PTVs showing a higher burden in DEE than in the common epilepsy types (Figure S14 ). In addition, both large 307 gene sets were more enriched for PTVs than for damaging missense variants. 308 309 Burden in candidate genetic etiologies associated with epilepsy 310 Among URVs in previously reported epilepsy genes, we found an expected and pronounced 311 difference in the number of singleton protein-truncating URVs in individuals with DEE relative to 312 controls. PTVs were associated with an increased DEE risk in 43 known dominant epilepsy 313 genes 17 (OR = 6.3, adjP = 2.1×10 -08 ), 50 known dominant DEE genes 9 (OR = 9.1, adjP = 7.8×10 -314 11 ), and 33 genes with de novo burden in neurodevelopmental disorders with epilepsy 9 (OR = 315 14.8, adjP =1.7×10 -12 ). Evidence for an excess of ultra-rare PTVs was also observed in individuals 316 with GGE, with an odds ratio ranging from 2 to 4. No enrichment of PTVs was observed among 317 people with NAFE (Figure 2A ; Table S8 ). In contrast, the burden of singleton missense (MPC≥2) 318 URVs was more pervasive across epilepsy types. Compared to controls, there was a 3.6-fold 319 higher rate of these missense URVs in established epilepsy genes in individuals with DEE (adjP 320 = 1.6×10 -10 ), a 2.3-fold elevation in individuals with GGE (adjP = 6.4×10 -07 ), and a 1.9-fold 321 elevation in individuals with NAFE (adjP = 2.8×10 -4 ). 324 Among brain-enriched genes-those defined as genes with at least a 2-fold increase in 325 expression in brain tissues relative to their average expression across tissues based on GTEx 326 data 32 -both protein-truncating and damaging missense (MPC≥2) URVs were significantly 327 enriched in epilepsy cases versus controls, and the missense burden was much higher than the 328 PTV burden (Figure S15) . We then investigated the burden in four smaller gene sets previously 329 implicated as mechanisms driving the etiology of epilepsy; these included 19 genes encoding 330 GABAA receptor subunits, 113 genes involved in GABAergic pathways, 34 genes encoding 331 excitatory receptors (ionotropic glutamate receptor subunits and nicotinic acetylcholine receptor 332 subunits), and 86 voltage-gated cation channel genes (e.g., sodium, potassium, calcium-full list 333 in Table S6 ) 18 . We discovered that, relative to damaging missense variants, the distribution of 334 PTVs in most of these gene sets did not differ significantly between epilepsy cases and controls 335 (Figure 2A ; Table 1 ). The PTV signals that remained significant after FDR correction included, 336 for individuals with DEE, an increased burden in GABAergic pathway genes and voltage-gated 337 cation channels, and noticeably, for individuals with GGE, an increased burden in the inhibitory 338 GABAA receptors (OR = 4.8, adjP = 0.021). No PTV burden was detected for individuals with 339 NAFE. In contrast, the enrichment of missense (MPC≥2) URVs was more extensive in these gene 340 sets across all epilepsy-control comparisons (Figure 2A ; Table 1 ). The burden of these damaging (Table S8) . These results support a recent finding where rare missense 350 variation in GABAA receptor genes conferred a significant risk to GGE 18 , and together implicate 351 the relative importance and involvement of damaging missense variants in abnormal inhibitory 352 neurotransmission in both rare and common epilepsy types. 353 For gene sets other than the three lists of previously associated genes (Table S6 ; 74 non-354 overlapping genes in total), we evaluated the residual burden of URVs after correcting for events 355 in the 74 known genes. For the gene sets of cation channel and neurotransmitter receptor genes, 356 the adjusted burden signals of singleton deleterious URVs was largely reduced, with some weak 357 associations remaining in GABAA receptor-encoding or GABAergic genes among individuals with DEE or GGE. For the larger gene groups of constrained genes and brain-enriched genes, burden 359 signals were attenuated but many remained significant, especially the strong enrichment of 360 missense MPC≥2 variants in brain-enriched genes across all three classes of epilepsy (Figure 361 S16). These findings suggest that although most gene burden is driven by previously identified 362 genes, more associations could be uncovered with larger sample sizes.
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Gene-based collapsing analysis recapture known genes for DEE 365 For gene discovery, because both protein-truncating and damaging missense (MPC≥2) URVs 366 showed an elevated burden in epilepsy cases, we aggregated both together as deleterious 367 pathogenic variants along with in-frame insertions and deletions in our gene collapsing analysis. 368 This amassed to a total of 46,917 singleton URVs and 52,416 URVs with AC≤3. Surprisingly, 369 for individuals diagnosed with DEE, we re-identified several of the established candidate DEE 370 genes as top associations (Figure 3A) . Although screening was not performed systematically, 371 many DEE patients were screened-negative for these genes using clinical gene panels prior to 372 enrollment. Based on the results of singleton URVs, SCN1A was the only gene that reached 373 exome-wide significance (OR = 18.4, P = 5.8×10 -8 ); other top-ranking known genes included 374 NEXMIF (previously known as KIAA2022; OR > 99, P = 1.6×10 -6 ), KCNB1 (OR = 20.8, P = 375 2.5×10 -4 ), SCN8A (OR = 13.8, P = 6.1×10 -4 ), and SLC6A1 (OR = 11.1, P = 3.6×10 -3 ) ( Table S10) . 376 Some carriers of deleterious URVs in lead genes were affected individuals with a normal result 377 for gene panel testing; for example, 2 out of the 3 carriers of qualified URVs for PURA and 2 out 378 of 5 for KCNB1 had undergone previous genetic screening. (Table S7 ). This could be because 379 different sample-contributing sites adopted different gene panels and not all of them included the 380 lead genes found to carry variants qualifying from this study, or that during screening patients 381 were found to carry a variant of uncertain significance that did not satisfy the ACMG guidelines 39 . 382 The gene burden results held up when considering URVs with AC≤3, often showing even stronger 383 associations; two other well-studied genes, STXBP1 (OR = 13.3, P = 1.4×10 -5 ) and WDR45 (OR 384 > 49, P = 1.2 × 10 -3 ), emerged on top, both of which have been implicated in DEE and 385 developmental disorders (Table S11) . 386 
387
Channel and transporter genes implicated in common epilepsies 388 When evaluating gene burden in the GGE and NAFE epilepsy subgroups, we did not identify any 389 exome-wide significant genes. However, several candidate epilepsy genes made up the lead 390 associations, including ion channel and transporter genes known to cause rare forms of epilepsy. 391 For the GGE case-control analysis in singleton deleterious URVs, the lead associations included 392 four previously-associated genes (EEF1A2, OR = 32, P = 3.8×10 -4 ; GABRG2, OR = 19.0, P = 393 6.2×10 -4 ; SLC6A1, OR = 7.3, P = 2.0×10 -3 ; and GABRA1, OR = 9.5, P = 2.2×10 -3 ), and two genes 394 (CACNA1G, OR = 9.1, P = 2.5×10 -4 ; UNC79, OR = 19.0, P = 6.2×10 -4 ) that were not previously 395 linked to epilepsy but are both highly expressed in the brain and under evolutionary constraint 396 (Figures 3B; Table S12 ). Although evidence has been mixed, CACNA1G was previously 397 implicated as a potential susceptibility gene for GGE in mutational analysis 40 and reported to 398 modify mutated sodium channel (SCN2A) activity in epilepsy 41 . UNC79 is an essential part of the 399 UNC79-UNC80-NALCN channel complex that influences neuronal excitability by interacting with 400 extracellular calcium ions 42 , and this channel complex has been previously associated with 401 infantile encephalopathy 43 . Notably, all these lead genes were more enriched for damaging 402 missense (MPC≥2) than for protein-truncating URVs despite the lower rate of MPC≥2 variants 403 relative to PTVs (Table S12) . 404 For individuals with NAFE, the analysis of singleton deleterious URVs identified LGI1 and 405 TRIM3 as the top two genes carrying a disproportionate number of deleterious URVs, however 406 neither reached exome-wide significance (OR > 32, P = 2.1×10 -4 ). GABRG2, a lead association 407 in individuals with GGE, was among the top ten most enriched genes, along with two brain-408 enriched, constrained genes (PPFIA3, OR = 8.2, P = 4.2×10 -3 ; and KCNJ3, OR = 16.4, P = 1.2×10 -3 ). GABRG2 has previously been reported to show an enrichment of variants compared 410 to controls in a cohort of individuals with Rolandic epilepsy (childhood epilepsy with 411 centrotemporal spikes) or related phenotypes, the most common group of focal epilepsies of 412 childhood 44 . Two other genes previously associated with epilepsy, DEPDC5 and SCN8A (both 413 OR = 5.5, P = 0.01), were among the top twenty associations (Figures 3C; Table S14 ).
LGI1 and 414 DEPDC5 are established genes for focal epilepsy, and DEPDC5 was the only exome-wide 415 significant hit in the Epi4K WES study for familial NAFE cases 17 . TRIM3 has not been previously 416 implicated in epilepsy, but evidence from a mouse model study implicates it in regulation of 417 GABAA receptor signaling and thus modulation of seizure susceptibility 45 . Single gene burden for 418 both GGE and NAFE remained similar when considering URVs with an allele count up to AC≤3 419 (Tables S13 & S15). Gene burden tests collapsing all epilepsy phenotypes recapitulated the lead 420 genes in each of the subgroup-specific analyses, but none of the genes achieved exome-wide 421 significance (Tables S16 & S17). It is worth noting that some of the genes were enriched for 422 deleterious URVs among the "controls", which is clearly driven by non-neuropsychiatric disease 423 ascertainment for many of the available controls (e.g., LDLR in Table S16 ; most control carriers 424 were individuals with cardiovascular diseases from the MIGen cohorts in Table S2 ). Thus, these 425 should not be interpreted as potential protective signals for epilepsy. 426 427 428 The secondary gene-based test of a recessive model did not identify genes that differed 429 significantly in the carrier rate of homozygous deleterious variants between epilepsy-affected 430 individuals and controls (Table S18 ). Even if we considered variants up to MAF < 0.01, for most 431 of the lead genes, only one case carrier was identified. For the DEE cohort, these genes included 432 recessive genes previously implicated, such as ARV1, BRAT1, CHRDL 46 with a homozygous PTV 433 and OPHN1 46 with a recessive missense (MPC≥2) variant (Table S18A ). For the two common 434 forms of epilepsy, a few studied recessive epilepsy genes were also observed in the lead gene 435 associations, such as SLC6A8 46 (a homozygous PTV) for GGE (Table S18B) , and SLC6A8 (a 436 homozygous missense-MPC) and SYN1 46 (a homozygous PTV) for NAFE (Table S18C) . One 437 GGE-affected individual was found homozygous for an in-frame deletion on CHD2, a dominant 438 DEE gene 46 (Table S18B ). These findings suggest an even larger cohort will be needed to identify 439 with clarity risk genes that act in a recessive manner for different groups of epilepsy. 440 Beyond URVs, we studied the contribution of low frequency deleterious variants to 441 epilepsy risk using SKAT (MAF < 0.01). Top associations for individuals with DEE included known 442 genes, such as missense-enriched STXBP1 (P = 9.3×10 -9 ), KCNA2 (P = 1.0×10 -5 ; Figure S17 ), 443 and PTV-enriched NEXMIF (P = 7.1×10 -8 ), and SCN1A (P = 3.9×10 -4 ; Figure S18 ). However, no Discussion 451 In the largest exome study of epilepsies to date, we show that ultra-rare deleterious coding 452 variation-variation absent in a large population-based exome database-is enriched in both rare 453 and common epilepsy syndromes when compared to ancestrally matched controls. When all 454 genes were considered in the tested gene sets, PTVs showed a more significant signal than 455 missense variants with an MPC≥2, and enrichment in deleterious URVs was more pronounced in 456 individuals diagnosed with DEE and GGE relative to NAFE. While no single gene surpassed 457 exome-wide significance in the non-hypothesis-driven analysis for GGE or NAFE, specific gene 458 groups previously associated with epilepsy or encoding biologically interesting entities showed a 459 clear enrichment of deleterious URVs. Specifically, we observed a significant excess of 460 deleterious URVs in constrained genes, established epilepsy genes, GABAA receptor subunit 461 genes, a larger group of genes delineating the GABAergic pathway, and all cation channel-462 encoding genes. Our results thus support the concept that defects in GABAergic inhibition 463 underlie various forms of epilepsy. These findings, based on a more than 5-fold increase in 464 sample size over previous exome-sequencing studies 17-19; 47 , clearly reveal observations that have 465 been hypothesized for common epilepsies from studies of rare, large monogenic families, and 466 confirm that the same genes are relevant in both settings. Thus, a further increase in sample size 467 will continue to unravel the complex genetic architecture of common epilepsies. Interestingly, no 468 enrichment was seen in genes encoding the excitatory glutamate and acetylcholine receptors. 469 For GGE, this difference between variants in inhibitory versus excitatory receptor genes may be 470 real, as excitatory receptor variants have not been shown so far in single subjects or families. In 471 NAFE, however, we suspect that it is probably due to a lack of power and/or genetic heterogeneity, 472 since genetic variants in specific subunits of nicotinic acetylcholine and NMDA receptors have 473 been described extensively in different types of non-acquired familial focal epilepsies 48 . 474 Notably, our overall finding of a mild to moderate burden of deleterious coding URVs in 475 NAFE (Figure 1 & 2) contrasts with results reported in the Epi4K WES study, where the familial 476 NAFE cohort showed a strong enrichment signal of ultra-rare functional variation in known 477 epilepsy genes and ion channel genes 17 . In addition, our findings for GGE showed a genetic risk 478 comparable or even stronger than the Epi4K familial GGE cohort. The strong signal in our GGE 479 cohort likely reflects the larger sample size, whereas the weaker signal in our NAFE cohort is 480 most likely due to differences in patient ascertainment. In Epi4K the cohort was deliberately We found that ultra-rare missense variants with an MPC score 28 ≥ 2 (2.0% of missense 501 variants) were enriched in individuals with epilepsy at an effect size approaching PTVs in the investigated gene groups. For common epilepsy types, the burden of these missense variants 503 (MPC≥2) was even more prominent than PTVs in known epilepsy genes and GABAergic genes 504 (Figure 2) . At the gene level, some of the top channel genes (e.g. GABRG2, CACNA1G) carried 505 a higher number of missense variants (MPC≥2) than PTVs in people with epilepsy. For instance, 506 in the gene-based collapsing analysis considering all epilepsies, 15 GABRG2 pathogenic variants 507 were found in epilepsy-affected individuals (including 7 GGE and 7 NAFE; Tables S12, 14 & 16) 508 versus only 1 pathogenic variant in controls; among the case-specific pathogenic variants, one 509 was a splice site mutation, while the other 14 were all missense variants (MPC≥2) (Figure S20) , 510 linking to an impaired channel function. This is in line with findings from a recent exome-wide 511 study of 6,753 individuals with neurodevelopmental disorder with and without epilepsy 9 that 512 detected an association of missense de novo variants with the presence of epilepsy, particularly 513 when considering only ion channel genes. A disease-association of missense variants rather than 514 PTVs points to a pathophysiological mechanism of protein-alteration (e.g., gain-of-function or 515 dominant-negative effects) rather than haploinsufficiency, but ultimately only functional tests can 516 elucidate these mechanisms. A recent study on the molecular basis of 6 de novo missense 517 variants in GABRG2 identified in DEE reported an overall reduced inhibitory function of GABRG2 518 due to decreased cell surface expression or GABA-evoked current amplitudes, suggesting 519 GABAergic disinhibition as the underlying mechanism 50 . Surprisingly, 2 of those recurrent de novo 520 missense variants were seen in two GGE-affected individuals in our study (A106T and R323Q), 521 and another recently reported variant in GABRB2 (V316I) also occurred both de novo in DEE 51 522 and as an inherited variant in a GGE family showing a loss of receptor function 18 . This suggests 523 that changes in protein function from the same missense pathogenic variant may cause not only 524 severe epilepsy syndromes, but also contribute to common epilepsies with milder presentations, 525 similar to what is known about variable expressivity in large families carrying GABRG2 variants 48; 526 52-54 . Reduced receptor function due to GABRG2 variants has been also shown for childhood 527 epilepsy with centrotemporal spikes previously 44; 54 , which belong to the NAFE group in this study. 528 Moving forward, discovering how variant-specific perturbations of the neurotransmission and 529 signaling system in a gene can link to a spectrum of epilepsy syndromes will require in-depth 530 functional investigation. 531 Although we have increased the sample size from the Epi4K and EuroEPINOMICS WES 532 studies for both GGE and NAFE subgroups by more than 5-fold, the phenotypic and genetic 533 heterogeneity of common epilepsies-on par with other complex neurological and 534 neuropsychiatric conditions-will require many more samples to achieve statistical power for 535 identifying exome-wide significant genes. Furthermore, while we implemented stringent QC to 536 effectively control for the exome capture differences between cases and controls, this 537 concomitantly resulted in a loss of a substantial amount of the called sites and reduced our 538 detection power to identify associated variants. As sample sizes grow, the technical variation 539 across projects and sample collections will remain a challenge in large-scale sequencing studies 540 relying on a global collaborative effort. 541 With this largest epilepsy WES study to date, we demonstrated a strong replicability of 542 existing gene findings in an independent cohort. GABAA receptor genes affected by predicted-543 pathogenic missense variants were enriched across the three subgroups of epilepsy. An ongoing 544 debate in epilepsy genetics is the degree to which generalized and focal epilepsies segregate 545 separately, and whether their genetic determinants are largely distinct or sometimes shared 4; 55 . 546 Whilst clinical evidence for general separation of pathophysiological mechanisms in these two 547 forms is strong, and most monogenic epilepsy families segregate either generalized or focal 548 syndromes, the distinction is not absolute. Here, the finding of rare variants in GABAA receptor 549 genes in both forms adds weight to the case for shared genetic determinants. 550 Our results suggest that clinical presentations of common epilepsy types with complex This analysis was restricted to 4,042 non-ExAC controls for comparison with epilepsy cases. We 831 focused on "ultra-rare" variants not observed in the DiscovEHR database. Significance of 832 association was displayed in FDR-adjusted p-values; odds ratios and 95% CIs were not 833 multiplicity adjusted. The five functional coding annotations were defined as described in Table   834 S5. PTV denotes protein-truncating variants; the "damaging missense" and "benign missense" identify genes with a differential carrier rate of these ultra-rare deleterious variants in individuals 863 with epilepsy compared to controls. Exome-wide significance was defined as p-value < 6.8e-07 864 after Bonferroni correction (Methods). Only SCN1A achieved exome-wide significance for 865 individuals with DEE. Table 1 . Enrichment of ultra-rare protein-truncating or damaging missense (MPC≥2) singletons in epilepsy This analysis compared the burden of deleterious pathogenic variants between cases and controls using logistic regression, adjusting for sex, the first ten principal components, and overall variant count. FDR correction was based on a full list of burden tests in Table S8 . Tested epilepsy types included all epilepsies (EPI; N=9,170), developmental and epileptic encephalopathies (DEE; N=1,021), genetic generalized epilepsy (GGE; N=3,108), and non-acquired focal epilepsy (NAFE; N=3,597). All were compared against 8,436 control samples. Figure 2 shows the enrichment pattern of PTVs and MPC≥2 variants across the seven gene sets listed here. Permutedlog 10 (P)
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